Widespread retina and optic nerve neuroinflammation in enucleated eyes from glaucoma patients

Carola Rutigliani1†, James R. Tribble1†, Anna Hagström1, Emma Lardner1,2, Gauti Jóhannesson3,4, Gustav Stålhammar1,2 and Pete A. Williams1*

Abstract

Neuroinflammation is recognized as a key component of neurodegenerative disease. In glaucoma, a common neurodegenerative disease and the leading cause of irreversible blindness, the evidence for neuroinflammation in patients is lacking. Animal models have demonstrated significant pro-inflammatory activation of resident glia in the retina, as well as influx of blood-derived monocytes and pro-inflammatory factors. Confirmation of this in human donor tissue has been challenging due to a lack of well-preserved and well-characterized post-mortem tissue. To address this we utilized archived, wax embedded eyes fixed immediately following enucleation from living glaucoma patients. We compared glaucoma to control eyes (enucleated for uveal melanoma where the tumor did not impact the central retina or optic nerve). We performed immunolabelling for neurodegenerative and glial markers (CD45, CD163, IBA1, GFAP, Vimentin) which were quantified by high-resolution light microscopy and image analysis in FIJI. Glaucoma eyes demonstrated significant neural loss consistent with advanced neurodegeneration. IBA1 and GFAP were significantly increased in the retina and optic nerve head of the glaucomatous eyes indicating that significant neuroinflammation had occurred which support findings in animal models. Inflammation is a treatable symptom of many diseases and as such, identification of earlier inflammatory processes in glaucoma could be important for potential future treatment options.

Keywords: Neuroinflammation, Retina, Glaucoma, Histopathology, Optic nerve, Microglia, Astrocytes

Introduction

Glaucoma is the leading cause of irreversible blindness affecting an estimated ~80 million people worldwide. With our increasingly aged population this burden will increase and is predicted to affect ~112 million people by 2040 [1]. In glaucoma, loss of vision occurs through the progressive death of retinal ganglion cells (RGCs), the output neurons of the retina. This manifests clinically as a thinning of the retinal nerve fiber layer (RNFL; RGC axons), the ganglion cell layer (GCL; RGC somas), and inner plexiform layer (IPL; RGC dendrites), and cupping/excavation of the optic nerve head (ONH; where RGC axons bundle and exit the eye as the optic nerve). Whilst the underlying mechanisms of glaucoma are still not fully understood, there is increasing evidence that the immune system may play a significant role in the disease [2]. Importantly, inflammation is a treatable symptom of many diseases and as such, identification of potential inflammatory processes that may occur in glaucoma could lead to viable, additive treatment opportunities for patients in the future.

†Carola Rutigliani and James R. Tribble contributed equally to this work
*Correspondence: pete.williams@ki.se
1 Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, 171 64 Stockholm, Sweden
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
The eye is often considered an immune privileged site [3]. However, an increasing number of studies have shown the importance of both resident and infiltrating immune cells in the initiation and progression of glaucoma. Animal models have demonstrated early and progressive pro-inflammatory activation of resident glia (microglia, astrocytes, and Müller glia), infiltration of monocytes and other blood leukocytes, up-regulation and release of cytokines/chemokines, especially the complement system, and activation of neurotoxic responses [4–10]. Targeting these processes directly has been demonstrated to delay or halt the neurodegenerative processes in glaucoma animal models. For example, the removal of systemic immune cells via gamma radiation, inhibition of microglia proliferation and activity (genetically or pharmacologically), and inhibition of the complement cascade [11–13].

A number of the neuroinflammatory features identified in animals have been demonstrated in human glaucoma patients. Histological studies of human retina have shown intense inflammatory staining in the ONH of glaucoma eyes [14], increased protein levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, and IFN-γ [15]) and infiltration of CD163+ macrophages to the optic nerve [16]. In human glaucomatous ONHs, astrocytes also expressed high levels of TNF-α and TNFR [17] and there is increased expression of toll-like receptors on retinal microglia and astrocytes [18]. The presence of a TNF-308 G/A polymorphism which leads to greater transcriptional activation has been demonstrated to be significantly higher in primary open-angle glaucoma and pseudoexfoliative glaucoma in specific populations [19, 20]. While a number of SNPs with the potential to affect inflammation have been identified to increase risk of glaucoma, these have been experimentally investigated in the context of intraocular pressure (IOP) and anterior chamber pathology [21]. Analysis of blood, aqueous humor, and vitreous has demonstrated the increased presence of TNF-α, complement components, autoantibodies, and other signs of inflammation [22–28]. Increased deposition of complement component 1Q (C1q) and 3 (C3) in particular have demonstrated to be well conserved inflammatory signals across animal models and human glaucoma samples [10]. Genetic deletion or pharmacological inhibition of C1q in animal models protects retinal ganglion cells, whereas C3 deletion worsens retinal ganglion cell survival [13, 29] reflecting the complex and time specific role of inflammation in glaucoma and the need for targeted therapies over broad anti-inflammatory strategies.

To date, there have been no successful clinical trials that assess an anti-inflammatory strategy in glaucoma. A major hurdle is the paucity of high quality human data with which to corroborate findings in animal models. The neural retina degrades rapidly following death [30], and this will inevitably lead to neurodegeneration and neuro-inflammation. Human retina at early disease time points with good tissue preservation are exceptionally rare. Linking donor-tissue to well established medical records for disease staging is also difficult (especially as follow-up intervals for established glaucoma patients may vary considerably). As such, whether blood derived immune cells infiltrate the retina in human glaucoma remains a contested issue. We aimed to determine whether neuroinflammation and immune infiltration were common, pervasive features of glaucoma by utilizing a unique resource of enucleated eyes from the archives of the St. Erik Ophthalmic Pathology Laboratory. The Ophthalmic Pathology archive at St. Erik Eye Hospital in Stockholm, Sweden includes ~3000 enucleated eyes preserved as paraffin wax tissue blocks with clinical records available for all patient eyes enucleated from 1960. Eye enucleations are performed due to ocular tumors, trauma, infection, and painful unresponsive glaucoma. Eyes are immediately put into 4% formalin following enucleation and wax embedded within 24 to 48 h. With national access to Sweden’s patient records, this represents a unique resource for glaucoma pathophysiology discovery.

Materials and methods

Ethics
Access to histopathology archive samples was fully covered through biobank #366 (St. Erik Eye Hospital). The study adhered to the tenets of the Declaration of Helsinki and the ethics protocols were approved by the Swedish Ethical Review Authority (2020-01525 and 2021-01036). This research followed the tenets of the Declaration of Helsinki.

Sample selection
Enucleation reports from the histopathology archive were screened to identify suitable eyes. Inclusion criteria included eyes where the majority of retina and entire optic nerve head was preserved without severe atrophy. Exclusion criteria included ongoing infection at time of enucleation, a mass (i.e. tumor, hemorrhage) covering central retina, and in vivo detached retina (i.e. as opposed to a processing artefact). Specific additional inclusion criteria for glaucoma eyes included eyes previously diagnosed with glaucoma or ocular hypertensive eyes or showing clinical signs of glaucoma at time of enucleation. Exclusion criteria were descriptions of complete retinal nerve fiber layer (RNFL) or inner retinal atrophy. Existing archived sections of selected eyes were evaluated by light-microscopy for complete optic disk excavation, complete degeneration of the ganglion cell layer (GCL) and/or RNFL, or complete optic nerve atrophy. Since
healthy eyes are not enucleated, eyes with uveal melanoma where the tumor did not infringe on the retina or optic nerve were used as controls (e.g. tumor confined to the iris and/or ciliary body and/or anterior choroid). Controls were selected by age and year of enucleation matching. Patients details are summarized in Table 1.

Immunohistochemistry
New ONH sections were cut from selected samples using a wax microtome (Thermo Scientific Microm HM355S). Tissue was sectioned at a thickness of 3 μm, placed on glass slides, and baked at 60 °C for 1 h. Chromogenic immunohistochemistry was performed using a Bond-III fully automated IHC and in situ hybridization machine (Leica Biosystems Division of Leica Microsystems Inc., Buffalo Grove, IL). Sections were deparaffinization in Bond DeWax solution followed by rehydration through an ethanol gradient. Antigen retrieval was performed by immersing in 1 mM EDTA buffer (pH 8.9–9.1) for 30 min at 100 °C. The sections were then washed and incubated in primary antibody for 15 min (Table 2). Slides were washed again and incubated in a polymer conjugated secondary antibody (BOND Polymer Refine Red Detection or BOND Polymer Refine Detection (DAB chromogen)) for 50 min at room temperature followed by color development for 15 min. Slides were counterstained with hematoxylin. Sections were dehydrated through an ethanol gradient, cleared in xylene, mounted in PERTEX, and covered with a coverslip.

Image acquisition and analysis
Tiled, color images of the whole retina and optic nerve were acquired at 40X magnification using a ZEISS Axio Scan.Z1 Digital Slide Scanner (Carl Zeiss). Regions of retina were cropped for analysis at 2 mm and 6 mm either side of the ONH center using Zen lite Software (version 3.3; Carl Zeiss). Crops of 1 mm were exported as Tiff Format (64bit, Big Tiff) images for analysis in FIJI. The ONH was exported as crops of 500 μm thickness starting from the optic disk surface and proceeding distally up to 2 mm. RBPMS + cells within the GCL were counted in crops (at 2 mm and 6 mm) in FIJI [31] and expressed as mean ± SEM. For immune cell counts, counts were performed manually along the entire retina within Zen lite. Cells were counted within the following retinal layers: ganglion cell complex (GCC, comprising the retinal nerve fiber layer, ganglion cell layer, and inner plexiform layer), inner nuclear layer (INL), outer plexiform layer (OPL), and outer nuclear layer (ONL). Cell counts were normalized to 100 μm of retina by measuring the retinal length along the ONL outer border in FIJI. For semi-quantitative analysis of signal intensity, crops of retina or ONH were color deconvoluted using a vector designed for DAB, FastBlue, and FastRed in FIJI. The channel corresponding to FastRed or DAB (depending on which stain was used) was retained (Mixed Red Refine, as used here, is the same chromogen as FastRed). This separated the signal of the chromogen targeted to the antibody from hematoxylin. The mean grey value (mean pixel intensity), and layer thickness were measured. Mean pixel intensity was inverted (value subtracted from 255) so that higher values corresponded to higher signal intensity. To determine the area of retina or ONH occupied by labelling, cropped images were binarized and particle analysis was performed in FIJI (Size: 0-Infinity; Circularity: 0–1) to give % area covered. Retinal values at 2 mm and 6 mm were averaged between either side of the ONH in glaucoma cases.

Statistical analysis
Statistical analyses were performed in R. Shapiro–Wilks tests confirmed that data were not normally distributed and so comparisons were made using non-parametric tests. For comparison within individual retina (i.e. paired test as for comparison of retina adjacent to the tumor and opposite the tumor in controls) a Wilcoxon signed-rank test was used. For comparison of control and glaucoma samples a Mann–Whitney U test was used. A statistically significant difference was defined as *P < 0.05 and categorized for graphics as *=P < 0.05, **=P < 0.01, ***P < 0.001, NS = non-significant (P > 0.05). For box plots, the center hinge represents the median with upper and lower hinges representing the first and third quartiles; whiskers represent 1.5 times the interquartile range.

Results
Significant retinal ganglion cell loss in late-stage glaucoma
We determined the extent of RGC loss in selected donor eyes with advanced vision loss and/or amaurosis. In controls we identified 67 (±9) and 31 (±6) RGCs/mm of retina at 2 and 6 mm eccentricity from the ONH respectively, but <1 RGC/mm in glaucomatous retina (0.25 ±0.2 and 0.08 ±0.08 at 2 and 6 mm) (Fig. 1A, B). Since single sections through the ONH may overestimate RGC loss due to a limited area of sampling we also stained NF-M in the RNFL. NF-M signal intensity was significantly reduced in the RNFL at 2 mm (44% relative to control) and 6 mm (32% relative to control) eccentricity and along the whole distance of the ONH (~40–45% relative to control) (Fig. 1C, D) demonstrating significant loss of RGC axons but with more remaining neural content than RBPMs counts alone would suggest.
Table 1  Clinical characteristics of glaucoma and control donors

| Sample ID | Eye | Condition | Sex | Age at enucleation (years) | Year of enucleation | Visual acuity (BCVA) | IOP (mmHg) | Years with glaucoma diagnosis |
|-----------|-----|-----------|-----|--------------------------|---------------------|----------------------|------------|-------------------------------|
| E0152-06  | R   | Glaucoma (unspecified) | F   | 87                        | 2006                | Amaurosis            | 57         | 23                           |
| E0554-05  | R   | Glaucoma (PEX)       | F   | 82                        | 2005                | Amaurosis            | 50         | 13                           |
| E0048-04  | R   | Glaucoma (PEX)       | F   | 86                        | 2004                | Amaurosis            | 48         | ~ 30                          |
| E0568-04  | L   | Glaucoma (neovascular) | F   | 77                        | 2004                | Amaurosis            | 50         | Unknown                       |
| E0472-03  | L   | Glaucoma (unspecified) | F   | 73                        | 2003                | Amaurosis            | 25         | Unknown                       |
| E0281-04  | L   | Glaucoma (POAG)      | F   | 89                        | 2004                | Amaurosis            | Last IOP not recorded | Unknown                       |
| E0469-04  | R   | Glaucoma (unspecified) | F   | 56                        | 2004                | Amaurosis            | Last IOP not recorded | Unknown                       |
| E0599-02  | R   | Glaucoma (unknown)   | M   | 34                        | 2003                | Amaurosis            | Last IOP not recorded | Unknown                       |
| E0245-07  | R   | Control              | M   | 86                        | 2007                | 0.2                  | 13         | NA                           |
| E0029-06  | L   | Control              | M   | 71                        | 2006                | NA                   | 12         | NA                           |
| E0300-06  | R   | Control              | F   | 71                        | 2006                | 0.1                  | 14         | NA                           |
| E0258-05  | L   | Control              | F   | 67                        | 2005                | 1                    | 14         | NA                           |
| E0330-05  | R   | Control              | M   | 85                        | 2005                | 0.2                  | 12         | NA                           |
| E0024-04  | R   | Control              | M   | 61                        | 2004                | 0.3                  | 10         | NA                           |
| E0271-02  | R   | Control              | F   | 69                        | 2002                | 1                    | 17         | NA                           |
| E0169-01  | L   | Control              | M   | 72                        | 2001                | 0.2                  | 11         | NA                           |
| E0214-01  | R   | Control              | F   | 77                        | 2001                | HR                   | 23         | NA                           |
| E0588-01  | R   | Control              | F   | 66                        | 2001                | FC 3 m               | 16         | NA                           |
| E0001-00  | R   | Control              | F   | 87                        | 2000                | Not recorded         | Not recorded | NA                           |
| E0471-00  | Unknown | Control   | M   | 61                        | 2000                | R: 0.8 L: 1.0       | Right: 16 Left: 17   | NA                           |

| Sample ID | Medications | Other diseases | Optic Nerve Status at Enucleation | Chamber angle/Iris Status at Enucleation |
|-----------|-------------|----------------|-----------------------------------|-----------------------------------------|
| E0152-06  | Cyanocobalamin (Vitamin B). Acetylsalicylic acid (Tromboocyte aggregation inhibitor). Furosemid (Loop-diuretic). Risperidone (Neurolepticum). Alprazolam (Benzodiazipine). Zopiclone (pyrazolopyrimidine). Propiomazin. Citalopram (SSRI). Mirtazapine (anti-depressive). Donepezil (Cholinesterase inhibitor). Lactulos (Laxitive). Hydroxizin. Paraffin, vaselin (Oculentum simplex) | Hypertension. Depression | Excavation and atrophy | Atrophy. Neovascularization. Occluded chamber angle |
| E0554-05  | Pravastatin (Statin). Sotalol (Beta receptor blocker). Klopigodogrel (Tromboocyte aggregation inhibitor). Digoxin. Furosemid (Loop diuretic). Nitroglycerin. Indometacin (NSAID). Lansoprazole (Proton pump inhibitor). Lactitil ( laxative) | Previous gall bladder operation. Hysterectomy and removal of ovaries. Heart infarction 1995. Angina. Heart failure. Cataract | Excavation and atrophy | Neovascularization. Mostly occluded chamber angle |
| E0048-04  | Diabetes medication. Irbesartan (Angiotensin II antagonist). Furosemid (Loop diuretic). Verapamil (Calcium antagonist). Digoxin. Allopurinol (xanthine oxidase inhibitor). Anastrozole (Non-steroidal aromatase inhibitor). Diclofenac (NSAID). Propiomazine (phenothiazines) | Diabetes Type II. Hypertension. Gout. Breat cancer operation in 2003 | Excavation and atrophy | Atrophy. Synechia and neovascularization of chamber angle |
### Table 1 (continued)

| Sample ID | Medications                                                                 | Other diseases                                                                 | Optic Nerve Status at Enucleation | Chamber angle/Iris Status at Enucleation |
|-----------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------|------------------------------------------|
| E0568-04  | Glibenclamide (Sulfonlyurea). Canbesartan (angiotensin receptor antagonist). Paracetamol (Acetaminophen). C-vitamin. Estradiol ( Estragen). Insulin (Actrapid, Mixtard, and Insulatard) | Neovascular glaucoma. Previous cholecystectomy. Hypertension. Diabetes. Mild dementia. Incontinence | Excavation and atrophy | Anterior synechiae. Neovascularization of chamber angle |
| E0472-03  | Latanoprost (Prostaglandin analog). Timolol (beta blocker). Estradiol, Norethisterone (Estrogen, Progestin) | Glaucoma and cataract left eye for several years. Otherwise healthy | Excavation and atrophy | Chamber angle partially occluded with anterior synechiae and neovascularization. Some iris neovascularization |
| E0281-04  | Unknown                                                                     | No other diseases recorded                                                      | Significant papillary excavation. Neovascularization and atrophy of opticus | Atrophy with neovascularization of iris and neovascularization of chamber angle |
| E0469-04  | Unknown                                                                     | Macular degeneration. Cataract                                                   | Excavation and atrophy | Some atrophy. Open chamber angle. No neovascularization |
| E0599-02  | Unknown                                                                     | Chronic uveitis                                                                  | Excavation and atrophy | Atrophy. Occluded chamber angle with anterior synechiae and neovascularization |
| E0245-07  | Bendroflumethiazide, Potassium chloride (Diuretic, electrolyte). Enalapril (ACE inhibitor). Atorvastatin (statin). Acetylsalicylic acid (Trombocyte aggregation inhibitor). Nitroglycerin | Operated prostate in 1983. Hypertension. Heart infarction in 2004. Angina         | No atrophy | Normal for age |
| E0029-06  | Enalapril (ACE inhibitor). Felodipine (Calcium antagonist). Bendroflumethiazide, Potassium chloride (Diuretic, electrolyte). Acetylsalicylic acid (Trombocyte aggregation inhibitor) | Operated prostate in 1997. Hip surgery for left hip x 2 with most recent surgery in 2004. Knee surgery for right knee in 2003. Stroke in 2003, since then hemiparesis with partial recovery | No atrophy | Tumor invasion. Chamber angle partially occluded by tumor |
| E0300-06  | Levothyroxine (thyroid hormone). Losartan (Angiotensin II receptor antagonist) Furosemid (Loop diuretic). Cyanocobalamin (Vitamin B). Estradiol ( Estragen). Amlodipine (Calcium antagonist) | No other diseases recorded                                                      | No atrophy | Tumor invasion |
| E0258-05  | Amlodipine (Calcium antagonist). Ranitidine (Anti-histamine)                | Hypertension                                                                      | No atrophy | Normal for age |
| E0330-05  | Diclofenac (NSAID)                                                          | Previously operated x 3 for kidney stones. Gout                                   | No atrophy | Normal for age |
| E0024-04  | No medications                                                              | Appendectomized                                                                   | No atrophy | Tumor invasion of the iris |
| E0271-02  | No medications                                                              | Healthy. Was admitted to a hospital many years prior due to a benign gynecological event | No atrophy | Normal for age |
| E0169-01  | No medications                                                              | Previously operated for mitralis insufficiency in April 2000 with plastic ring. Pacemaker since fall 2000 | No atrophy | Normal for age |
| E0214-01  | No medications                                                              | Healthy. No previous operations                                                  | No atrophy | NA |
| E0588-01  | Amitriptylin (tricyclic antidepressant). Atenolol (Beta receptor blocker). Estradiol (Estragen) | Recurring depression                                                             | No atrophy | Tumor invasion |
| E0001-00  | Unknown                                                                     | No other diseases recorded                                                      | No atrophy | Normal for age |
| E0471-00  | No medications                                                              | Previously healthy                                                                | No atrophy | Normal for age |
### Table 2 Antibody details

| Antibody | Supplier       | Ref. NR | Host | Dilution | Chromogen                |
|----------|----------------|---------|------|----------|--------------------------|
| RBPMS    | Novus Biologicals | NBP2-2011 | Rabbit | 1:400    | BOND Polymer Refine Red  |
| NF-M     | Novus Biologicals | NB300-222 | Chick | 1:2000   | BOND Polymer Refine Detection (DAB) |
| CD45     | DAKO           | M0701   | Mouse | 1:100    | BOND Polymer Refine Red  |
| CD68     | DAKO           | M 0876  | Mouse | 1:100    | BOND Polymer Refine Red  |
| CD163    | Abcam          | ab182422 | Rabbit | 1:200    | BOND Polymer Refine Red  |
| IBA1     | Abcam          | ab178846 | Rabbit | 1:500    | BOND Polymer Refine Red  |
| GFAP     | Abcam          | ab4648  | Mouse | 1:1000   | BOND Polymer Refine Red  |
| Vimentin | Dako           | M0725   | Mouse | 1:1000   | BOND Polymer Refine Red  |

**Fig. 1** Significant retinal ganglion cell loss has occurred in late-stage glaucoma. A Control and glaucomatous retinas were labelled for RBPMS (red) to determine RGC density. 40X tiled images were cropped to 1000 μm of retina at 2 mm (central) and 6 mm (peripheral). B RGC density was significantly reduced in both central and peripheral retina with an almost complete absence of RGCs in the glaucoma samples. C Axon density was estimated by NF-M staining in the RNFL in retina and in the optic nerve head (brown). D Signal intensity was significantly reduced in the RNFL in both central and peripheral retina and along the whole ONH suggesting a significant loss of axon density. These suggest that all glaucoma samples are at a late-disease stage with significant retinal ganglion cell loss. Scale bar = 200 μm in A and C (retina), 500 μm in C (ONH). **= P < 0.01, ***= P < 0.001. C=Control, G=Glaucoma. RBPMS = RNA-bending protein with multiple splicing, RGC = retinal ganglion cell, NF-M = Neurofilament medium, RNFL = retinal nerve fiber layer, ONH = optic nerve head.
No detectable active monocyte infiltration in late-stage glaucoma

Data from animal models suggests significant monocyte infiltration during early and late ocular hypertensive events and/or proliferation of microglia within inflamed tissue [8, 9]. However, it is currently unknown as to whether this occurs in human glaucoma. To assess the presence and degree of circulating monocyte entry into the retina and optic nerve in glaucoma we compared labelling of microglial, monocyte, and pan-leukocyte markers. Since control tissue were cases of ocular tumors, we first established the impact of a retinal tumor on inflammation and immune infiltration. As expected, tumors were immune cell rich and the retina on the side of the tumor had significantly higher numbers of immune cells (4.3 fold greater number of CD45+, 2.4 fold greater number of CD163+, 1.9 fold greater number of IBA1+) in comparison to the opposite side of the retina (Additional file 1: Fig. S1). We subsequently used only the retina opposite the tumor for comparisons of glaucoma to controls. In control and glaucoma retina, there were few cells positive for the pan-leukocyte marker CD45, and this was not significantly different between groups (Additional file 2: Fig. S2A–C). This was similar in the ONH, where signal intensity and the percentage of the area of the ONH occupied by staining was low (<1% area) (Additional file 2: Fig. S2B–C). This trend was similar for the monocyte marker CD163. Few CD163+ cells per mm of retina were detected and signal intensity and area occupied were low in the ONH (<1% area). There was no significant difference between control and glaucoma (Additional file 2: Fig. S2D–F). Labelling with the microglia/macrophage-specific marker IBA1 identified a greater number of cells in the retina and ONH (Fig. 2). IBA1+ cells in controls displayed ramified morphology typical of normal surveilling microglia. In glaucomatous retina, IBA1+ cells were more condensed around the nucleus as is typical of microglia which have shifted to a pro-inflammatory phenotype. There were numerous ameboid IBA1+ cells typical of pro-inflammatory, phagocytic microglia, or infiltrating monocytes. These cells were concentrated towards the inner border of the ILM. In addition, rod-like/bipolar-like IBA1+ cells were also concentrated at the inner border of the ILM. These are reminiscent of microglia observed in the NFL of animal models of glaucoma which align towards the ONH. IBA1+ cell density increased in the GC complex (260% of control) and INL (170% of control) but not in the ONL and OPL in glaucoma, consistent with neuroinflammation of only the inner retina mirroring neurodegeneration of only the inner retina as is observed in glaucoma (Fig. 2A–C). Both signal intensity (>25 AU) and area occupied (~10%) in the ONH were higher for IBA1 staining than CD45 and CD163. There was a significant increase in both signal intensity (178% of control) and area occupied (148% of control) within the first 500 µm of the ONH in glaucoma (Fig. 2B, C), suggesting an increase in inflammation in the pre-myelinated optic nerve.

Retina and optic nerve are extensively gliotic in late-stage glaucoma

GFAP and vimentin are type III intermediate filament proteins that are upregulated in astrocytes and Müller cells in response to inflammatory activation [32]. Intense GFAP and vimentin staining was observed across the retina and ONH in both controls and glaucoma (Fig. 3A–F). GFAP signal intensity (183% of control) and area occupied (190% of control) was significantly higher in glaucoma at 2 mm eccentricity but not at 6 mm (Fig. 3A–C). Stellate astrocyte morphology was evident in the NFL in control but in glaucoma retinas there were no distinguishable individual cells, rather the network had become interwoven. GFAP expression was also evident within Müller processes (transverse along retinal layers). These are clear indications of significant gliosis. In the ONH, GFAP signal intensity (~200% of control on average) and area occupied (~190% of control on average) was significantly higher in glaucoma along the whole distance of the ONH (Fig. 3B, C). Vimentin was variable in both conditions in the retina and was not significantly different (Fig. 3D–F) but transverse Müller processes were again more evident. Vimentin was significantly greater in the ONH in glaucoma, with higher signal intensity (~195% of control on average) and area occupied (~200% of control on average) up to 1.5 mm along the ONH (Fig. 3E, F). These demonstrate significant gliosis of the retina and ONH in glaucoma, consistent with previous inflammatory insult.

Discussion

We identified significant RGC loss in glaucomatous samples consistent with late-stage disease. We identified a significant increase in density and volume of microglia/macrophages and gliosis in the retina and ONH in these glaucomatous eyes but with no evidence of actively infiltrating monocytes (findings summarized in Table 3).

Across multiple species and models of glaucoma, inflammation has been identified as a common feature of the disease. Importantly, inflammation in this context is not a bystander event, but is an active exacerbator of RGC neurodegeneration. Supporting this, strategies to prevent or limit inflammation have been demonstrated to provide robust protection of RGCs, extending the period of their viability. These treatments do not address intrinsic susceptibilities or dysfunctions of RGCs and so will not completely arrest neurodegeneration, but they could...
Fig. 2 Microglial and monocyte morphology and density are increased in glaucoma, consistent with increased neuroinflammatory activation. Control and glaucomatous retinas were labelled for IBA1 (red) to visualize microglia/macrophages. A Whole retina (tiled 40X images) and B ONH were imaged and analyzed. C) IBA1+ cells were counted by retinal layer across the whole retinal length, demonstrating a significant increase in cell density in the GCC and INL, but not in the OPL or ONL, consistent with inner retinal inflammation. The difference in IBA1+ cell morphology between control and glaucoma samples is highlighted in inset i-iv in A. IBA1+ cells in control retina demonstrate ramified processes (i, ii) consistent with homeostatic resting microglia. In comparison, in glaucoma IBA1+ cells have an amoeboid appearance (iii) consistent with pro-inflammatory phenotypes, or spindle/bipolar phenotypes (iv) at the RNFL/ILM border as are typical in animal models of glaucoma. Microglia/macrophages in control ONH (v) were restricted to areas between axon bundles but this spatial distribution was lost in glaucoma with microglia spread across the whole ONH suggesting proliferation or migration to areas of inflammation. This could also reflect the aftereffects of monocyte infiltration. In the ONH, microglial density and signal intensity was significantly increased within the first 500 µm, suggesting the presence of pro-inflammatory response in the laminar region. Scale bar = 200 µm in A, 500 µm in B. * = P < 0.05, ** = P < 0.01. C = Control, G = Glaucoma. IBA1 = ionized calcium-binding adapter molecule 1, ONH = optic nerve head, GCL = ganglion cell layer, INL = inner nuclear layer, OPL = outer plexiform layer, ONL = outer nuclear layer, RNFL = retinal nerve fiber layer, ILM = inner limiting membrane
nevertheless prove to be ideal adjuvant treatments alongside existing IOP lowering therapies and new emerging strategies. Glaucoma shares many common features with other neurodegenerative diseases including Alzheimer’s disease and multiple sclerosis, where neuroinflammation is the prime therapeutic target [33]. Repurposing existing drugs or those which have passed safety trials but failed to show disease specific benefits, may represent a valuable strategy to deliver additional therapeutic benefits to glaucoma patients beyond conventional IOP lowering treatment. The major barrier to this is a lack of translational data supporting the occurrence of inflammatory events and mechanisms in human glaucoma as described in animal models. This is the result of a paucity of available and suitable human tissue. Since patients do not die from glaucoma it is difficult to acquire tissue at early disease stages where the quality of tissue is not confounded by the cause of death, or where there is not significant time post-mortem prior to tissue collection. We utilized enucleated eyes to diminish these issues. Since this tissue is not acquired post-mortem and is fixed immediately after enucleation, it is free of neurodegenerative and neuroinflammatory confounders that can be induced in degrading retina. We previously used post-mortem tissue from glaucoma patients fixed within ~2 h of death and experienced significant neural changes at a gross- and ultra-structural level [30]. Although the enucleated eyes used here were late/end-stage disease, identification of ongoing or past inflammation can be reliably attributed to the disease process.

We identified a significant increase in density and volume of microglia/macrophages and gliosis in the retina and ONH. We did not detect any specific labeling of actively infiltrating monocytes, but we cannot rule out the presence of integrated monocytes that have become microglia-like monocyte-derived macrophages. These infiltrating cells adopt phenotypes of resident cells, in the central nervous system this includes expression and upregulation of genes previously considered specific markers of resident microglia (e.g. IBA1). This process has now been well characterized and has been demonstrated in animal models of Alzheimer’s disease and retinal photoreceptor degeneration [34–37]. In animal models of glaucoma, both active extravasation of monocytes and passive entry of monocytes (leakage) has been demonstrated [8, 38] as well as blood-retina-barrier disruption [7, 39]. It is yet to be determined whether such blood-retina-barrier breakdown exists in human glaucoma patients, and as such, we cannot distinguish whether the immune cells that have entered have done so via an active or passive mechanism. Margeta et al., previously demonstrated significant monocyte infiltration to the ONH in glaucoma [16]. This may occur as an earlier disease feature, as is observed in animal models of glaucoma, and by later disease stages this process may have ceased. It is unclear whether the cells present in this study have entered through via an active or passive mechanism. Further studies could distinguish whether blood-retina-barrier integrity in post-mortem human samples is disrupted. Alternatively, the post-mortem time of >10 h in all samples used by Margeta et al. may have resulted in significant monocyte infiltration or leakage into tissue post-mortem, which was further enhanced in glaucomatous eyes. This would not have occurred in our enucleated samples. It is possible the high levels of gliosis which we detected may present a barrier to further immune cell infiltration at later disease time points. Much of the lost neural content in the glaucoma cases was replaced by astrocyte and Müller processes in the inner retina and ONH. This will also prove a significant barrier to RGC replacement or regenerative therapeutic approaches.

Strengths and limitations
Labelling for CD45 and CD163 was weak. This likely reflects the difficulty staining tissue that has been...
Fig. 3 (See legend on previous page.)
preserved in paraffin wax for >10 years. While some antibodies worked well with intense staining following antigen retrieval, CD45 and CD163 were not as pervasive as expected which may have resulted in underreporting of their abundance. Using more concentrated antibody resulted only in non-specific labelling and a difficulty in resolving cells against background signal. This further emphasizes the difficulty in confirming animal model findings in glaucoma human tissue. A potential weakness of this study is that glaucoma cases include a number of differing types of glaucoma (POAG, PEX, and unspecified). These could differ in the degree of inflammation, particularly if related to the degree of neuronal decline, and subdividing types would provide a more comprehensive analysis of inflammation given a greater number of available samples. Well characterized, and well-preserved glaucoma samples from earlier in disease will be necessary to fully assess inflammation at earlier disease tiem-points (however, access to this tissue is likely to be a major barrier). It is essential to elucidate early markers and mechanisms of inflammation in human samples if immunomodulatory therapies are to be successfully translated from animal studies. Animal models have demonstrated that strategies targeting neuroinflammation are highly time and context dependent. Attempting to prevent inflammation can be profoundly neuroprotective, and so an understanding of how early inflammation occurs will be important in determining which of these strategies can be clinically employed. Although this study only identifies inflammation as a feature of late disease, this at least supports that inflammatory events have occurred and/or are ongoing. These data do not rule out inflammation occurring only as a tombstone of the disease. However, if inflammation is only a byproduct of significant RGC degeneration, then this does not preclude anti-inflammatory therapies as viable strategies to limit acceleration of RGC degeneration much in the same way that current IOP lowering therapies do not target a causative disease feature. The main strength of this study is that the inflammatory changes identified are free from confounders related to the degree of tissue integrity and preservation.

### Conclusions

We identify evidence of widespread inflammation in the absence of post-mortem confounders in glaucomatous retina and optic nerve heads which support findings in animal models. These samples represent late/advanced disease stages; further evidence of early inflammation is critical to advance understanding of a potential role of inflammation in human glaucoma pathophysiology.

### Supplementary Information

The online version contains supplementary material available at [https://doi.org/10.1186/s40478-022-01427-3](https://doi.org/10.1186/s40478-022-01427-3).

### Table 3 Qualitative summary of staining

| Marker | Condition | CD45 | CD168 | IBA1 | GFAP | Vimentin |
|--------|-----------|------|-------|------|------|----------|
| Retina | Control   | Low  | Low   | +    | +    | ++       |
|        | Glaucoma  | Low  | Low   | +++  | ++   | ++       |
| ONH    | Control   | Low  | Low   | ++   | +    | +        |
|        | Glaucoma  | Low  | Low   | +++  | ++   | ++       |

### Abbreviations

GCC: Ganglion cell complex; GCL: Ganglion cell layer; GFAP: Glial fibrillary acidic protein; IBA1: Ionized calcium-binding adapter molecule 1; INL: Inner nuclear layer; IOP: Intraocular pressure; IPL: Inner plexiform layer; NF-M: Neurofilament medium; ONH: Optic nerve head; ONL: Outer nuclear layer; OPL: Outer plexiform layer; RBPMS: RNA-binding protein with multiple splicing; RGC: Retinal ganglion cells; RNFL: Retinal nerve fiber layer.

### Additional file 1: Fig. S1

Retina opposite the tumor has significantly less immune cell labelling than retina adjacent to the tumor in uveal melanoma eyes. Since healthy eyes are not enucleated, uveal melanoma cases where the tumor did not infringe on the central retina or optic nerve were used as controls. To determine the influence of the tumor on immune cells in the retina, cell counts of CD45+, CD16+, and IBA1+ cells were performed on retina each side of the ONH. Results were compared from the retina adjacent to the tumor (tumor side, TS) or opposite the tumor (opposite side, OS). A An example control eye showing the overview of the whole section where the tumor is visible in the upper right of the vitreous chamber and example images of IBA1+ cells from the tumor side (right) and opposite side (left). B There was a significantly greater number of CD45+, CD163+, and IBA1+ cells in the GCC on the tumor side relative to the opposite side. There was also a significant increase in IBA1+ cells in the INL on the tumor side relative to the opposite side. These data indicate that the opposite side represents the best approximation of normal retina and as such only the opposite side to the tumor was analyzed in all control eyes when comparing to glaucoma eyes. Scale bar = 5 mm in A (upper) and 200 µm in A (lower). * = P<0.05, ** = P<0.01. C Control, G = Glaucoma. GCC = ganglion cell complex, IBA1 = ionized calcium-binding adapter molecule 1, INL = inner nuclear layer, ONH = optic nerve head, OS = opposite side.

### Additional file 2: Fig. S2

Minimal labelling of CD45+ and CD163+ cells in control and glaucoma retina. Control and glaucomatous retinas were labelled for CD45 (red) to visualize leukocytes in A the retina and B the ONH. Few CD45+ cells were observed in either condition and these were predominantly observed in the GCC in both control (i) and glaucoma (ii) retinas. There were more CD45+ cells in the ONH but there was not clear order to their distribution (iii, iv). C Cell counts of CD45+ cells identified no significant difference in cell density between control and glaucoma across all retinal layers. In the ONH there was no significant difference in signal intensity or area occupied by labelling. Control and glaucomatous retinas...
Acknowledgements
The authors would like to thank St. Erik Eye Hospital for financial support for research space.

Author contributions
CR performed experiments, analyzed data, wrote the manuscript; JRT conceived and designed experiments, analyzed data, wrote the manuscript; AH performed experiments, analyzed data, wrote the manuscript; EL performed experiments; GS designed experiments, wrote the manuscript; PAW conceived and designed experiments, wrote the manuscript. All authors read and approved the final manuscript.

Funding
Open access funding provided by Karolinska Institutet. This research was funded by Vetenskapsrådet 2018-02124 (PAW), Karolinska Institutet Foundation Grants for Eye Research, and Karolinska Institutet Research Foundation Grants (JRT). PAW is supported by Karolinska Institutet in the form of a Board of Research Faculty Funded Career Position and by St. Erik Eye Hospital philanthropic donations.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Access to histopathology archive samples was fully covered through biobank #366 (St. Erik Eye Hospital). The study adhered to the tenets of the Declaration of Helsinki and the ethics protocols were approved by the Swedish Ethical Review Authority (2020-01525 and 2021-01036).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, 171 64 Stockholm, Sweden. 2St. Erik Eye Hospital, 171 64 Stockholm, Sweden. 3Department of Clinical Sciences, Ophthalmology, Umeå University, 901 85 Umeå, Sweden. 4Wallenberg Centre of Molecular Medicine, Umeå University, 901 85 Umeå, Sweden.

Received: 16 June 2022 Accepted: 10 August 2022
Published online: 19 August 2022

References
1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121:2081–2090
2. Bauböhn C, Kolko M, Melik-Parsadaniantz S, Messmer EM (2021) Inflammation in glaucoma: from the back to the front of the eye, and beyond. Prog Retin Eye Res 83:100916
3. Taylor AW (2016) OcULAR immune privilege and transplantation. Front Immunol 7:37
4. Bosco A, Steele MR, Vetter ML (2011) Early microglia activation in a mouse model of chronic glaucoma. J Comp Neurol 519:599–620
5. Breen KT, Anderson SR, Steele MR, Calkins DJ, Bosco A, Vetter ML (2016) Loss of fractalkine signaling exacerbates axon transport dysfunction in a chronic model of glaucoma. Front Neurosci 10:526
6. Gramlich OW, Teister J, Neumann M, Tao X, Beck S, von Pein HD et al (2016) Immune response after intermittent minimally invasive intracocular pressure elevations in an experimental animal model of glaucoma. J Neuroinflammation 13:82
7. Howell GR, Macalinao DG, Sousa GL, Walden M, Soto I, Kneeland SC et al (2011) Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Investig 121:1429–1444
8. Williams PA, Braine CE, Kizhatil K, Foxworth NE, Tolman NG, Harder JM et al (2019) Inhibition of monocyte-like cell extravasation protects from neurodegeneration in DBA/2J glaucoma. Mol Neurodegener 14:6
9. Tribble JR, Kokkali E, Otmani A, Plastino F, Lardner E, Vohra R et al (2021) When is a control not a control? Reactive microglia occur throughout the control contralateral pathway of retinal ganglion cell projections in experimental glaucoma. Transl Vis Sci Technol 10:22
10. Stasi K, Nagel D, Yang XY, Wang RF, Ren LZ, Podos SM et al (2006) Complement component 1Q (C1Q) upregulation in retina of murine, primate, and human glaucomatous eyes. Invest Ophthalmol Vis Sci 47:1024–1029
11. Howell GR, Soto I, Zhu X, Ryan M, Macalinao DG, Sousa GL et al (2012) Radiation treatment inhibits monocyte entry into the optic nerve head and prevents neuronal damage in a mouse model of glaucoma. J Clin Investig 122:1246–1261
12. Bosco A, Crish SD, Steele MR, Romero CO, Inman DM, Horner PJ et al (2012) Early reduction of microglia activation by irradiation in a model of chronic glaucoma. PLoS ONE 7:e43602
13. Williams PA, Tribble JR, Pepper KW, Cross SD, Morgan BP, Morgan JE et al (2016) Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma. Mol Neurodegener 11:1–13
14. Yuan L, Neufeld AH (2001) Activated microglia in the human glaucomatous optic nerve head. J Neurosci Res 64:523–532
15. Gramlich OW, Beek S, von Thun Und Hohenstein-Blaul N, Boehm N, Ziegler A, Vetter JM et al (2013) Enhanced insight into the autoimmune component of glaucoma: IgG autoantibody accumulation and pro-inflammatory conditions in human glaucomatous retina. PLoS ONE 8:e57557
16. Margeta MA, Lad EM, Proia AD (2018) CD163+ macrophages infiltrate axon bundles of postmortem optic nerves with glaucoma. Graefes Arch Clin Exp Ophthalmol 256:2449–2456
17. Tezel G, Li LY, Patil RV, Wax MB (2001) TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 42:1787–1794
18. Tezel G, Yang X, Luo C, Kain AD, Powell DW, Kuehn MH et al (2010) Oxidative stress and the regulation of complement activation in human glaucomatous retina. Invest Ophthalmol Vis Sci 51:5071–5082
19. Razeghinejad MR, Rahat F, Kamali-Sarvestani E (2009) Association of TNFA -308 G/A and TNFRI -866 A/G gene polymorphisms with glaucoma. Ophthalmic Res 42:118–124
20. Brzekut B, Mesić L, Irkic M, Ozdag BB, Sanal O, Arslan U et al (2012) Association of tumour necrosis factor-alpha -308 G/A polymorphism with primary open-angle glaucoma. Clin Exp Ophthalmol 40:e156–e162
21. Choquet H, Paylakhi S, Kneeland SC, Thai KK, Hoffmann TJ, Yin J et al (2018) A multithenic genome-wide association study of primary open-angle glaucoma identifies novel risk loci. Nat Commun 9:2278
22. Kondkar AA, Sultan T, Almobarak FA, Kalantan H, Al-Obeidan SA, Abu-Amero KK (2018) Elevated levels of plasma tumor necrosis factor alpha in patients with pseudoexfoliation glaucoma. Clin Ophthalmol 12:153–159
23. Kondkar AA, Sultan T, Almobarak FA, Kalantan H, Al-Obeidan SA, Abu-Amero KK (2018) Association of increased levels of plasma tumor necrosis factor alpha with primary open-angle glaucoma. Clin Ophthalmol 12:701–706
24. Joachim SC, Bruns K, Lackner KJ, Pfeiffer N, Grus FH (2007) Antibodies to alpha B-crystallin, vimentin, and heat shock protein 70 in aqueous humor
of patients with normal tension glaucoma and IgG antibody patterns against retinal antigen in aqueous humor. Curr Eye Res 32:501–509
25. Sharma S, Bollinger KE, Kodeboyna SK, Zhi W, Patton J, Bai S et al (2018) Proteomic alterations in aqueous humor from patients with primary open angle glaucoma. Invest Ophthalmol Vis Sci 59:2635–2643
26. Hubens WHG, Beckers HJM, Gorgels TGMF, Webers CAB (2021) Increased ratios of complement factors C3a to C3 in aqueous humor and serum mark glaucoma progression. Exp Eye Res 204:108460
27. Li S, Li D, Shao M, Cao W, Sun X (2018) Decreased serum levels of complement c3 reflect complement system dysregulation in patients with primary open-angle glaucoma: results from a pilot study. J Glaucoma 27:761–768
28. Taube AB, Hardenborg E, Wetterhall M, Artemenko K, Hanrieder J, Anderson M et al (2012) Proteins in aqueous humor from cataract patients with and without pseudoxefoliation syndrome. Eur J Mass Spectrom (Chichester) 18:331–341
29. Harder JM, Braine CE, Williams PA, Zhu X, MacNicol KH, Sousa GL et al (2017) Early immune responses are independent of RGC dysfunction in glaucoma with complement component C3 being protective. Proc Natl Acad Sci U S A 114:E3839–E3848
30. Tribble JR, Vasalauskaite A, Redmond T, Young RD, Hassan S, Fautsch MP et al (2019) Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma. Brain Commun 1:fcz035
31. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682
32. Vecino E, Rodriguez FD, Ruzafa N, Pereiro X, Sharma SC (2016) Glia-neuron interactions in the mammalian retina. Prog Retin Eye Res 51:1–40
33. Fu WY, Wang X, Ip NY (2019) Targeting neuroinflammation as a therapeutic strategy for Alzheimer’s disease: mechanisms, drug candidates, and new opportunities. ACS Chem Neurosci 10:872–879
34. Lund H, Pieber M, Parsa R, Han J, Grommisch D, Ewing E et al (2018) Competitive repopulation of an empty microglial niche yields functionally distinct subsets of microglia-like cells. Nat Commun 9:4845
35. Théraulaz P, EIAI A, Rivest S (2015) The dynamics of monocytes and microglia in Alzheimer’s disease. Alzheimer’s Res Ther 7:41
36. Rønning KE, Karlen SJ, Miller EB, Burns ME (2019) Molecular profiling of resident and infiltrating mononuclear phagocytes during rapid adult retinal degeneration using single-cell RNA sequencing. Sci Rep 9:4858
37. Ma W, Zhang Y, Gao C, Fariss RN, Tam J, Wong WT (2017) Monocyte infiltration and proliferation reestablish myeloid cell homeostasis in the mouse retina following retinal pigment epithelial cell injury. Sci Rep 7:8433
38. Williams PA, Braine CE, Foxworth NE, Cochran KE, John SWM (2017) GlyCAM1 negatively regulates monocyte entry into the optic nerve head and contributes to radiation-based protection in glaucoma. J Neuroinflammation 14:93
39. Alarcon-Martinez L, Shiga Y, Villafranca-Baughman D, Belforte N, Quintero H, Dottigny F et al (2022) Pericyte dysfunction and loss of interpericyte tunneling nanotubes promote neurovascular deficits in glaucoma. Proc Natl Acad Sci USA 119:e2110329119

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.